Pipeline

Our macrocyclic platform has fueled our pipeline of highly potent, proprietary kinase inhibitors that are structurally different from many existing kinase inhibitors and may address the key issues of emerging treatment resistance and toxicities that limit duration of treatment. We hold global development and commercialization rights to all of our drug candidates.